Logo

CON

Concentra Group Holdings Parent, Inc.

CON

Concentra Group Holdings Parent, Inc. • NYSE
$20.56 ▼ -1.30% (-0.27)
Market Cap $2.64 B
52w High $24.17
52w Low $18.55
Dividend Yield 0.19%
P/E 17.57
Volume 214.27K
Outstanding Shares 128.17M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $572.8M ▲ $72.793M ▲ $48.259M ▲ 8.425% ▲ $0 ▼ $114.381M ▲
Q2-2025 $550.785M ▲ $71.909M ▲ $44.56M ▲ 8.09% ▲ $0.35 ▲ $108.54M ▲
Q1-2025 $500.752M ▲ $63.332M ▲ $38.911M ▲ 7.771% ▲ $0.31 ▲ $96.063M ▲
Q4-2024 $465.041M ▼ $61.103M ▼ $21.512M ▼ 4.626% ▼ $0.17 ▼ $74.697M ▼
Q3-2024 $489.638M $88.656M $44.338M 9.055% $0.35 $101.447M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $49.941M ▼ $2.844B ▲ $2.434B ▼ $385.488M ▲
Q2-2025 $73.872M ▲ $2.842B ▲ $2.474B ▲ $342.636M ▲
Q1-2025 $52.109M ▼ $2.729B ▲ $2.398B ▼ $307.119M ▲
Q4-2024 $183.255M ▲ $2.699B ▲ $2.4B ▲ $275.671M ▼
Q3-2024 $136.822M $2.481B $2.18B $277.78M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $48.259M ▲ $60.627M ▼ $-20.468M ▲ $-64.09M ▼ $-23.931M ▼ $39.418M ▼
Q2-2025 $44.56M ▲ $88.379M ▲ $-79.508M ▲ $12.892M ▼ $21.763M ▲ $63.153M ▲
Q1-2025 $40.642M ▲ $11.699M ▼ $-294.749M ▼ $151.904M ▲ $-131.146M ▼ $-4.033M ▼
Q4-2024 $22.8M ▼ $93.714M ▲ $-16.686M ▲ $-30.595M ▼ $46.433M ▼ $77.026M ▲
Q3-2024 $44.338M $65.908M $-16.964M $37.209M $86.153M $50.763M

Five-Year Company Overview

Income Statement

Income Statement Revenue has been growing steadily, but at a moderate pace, suggesting a mature business that is still expanding rather than a fast-growth story. Profitability at the operating level has improved slightly over time, with better margins than a few years ago, which hints at good cost control and scale benefits. However, net profit and earnings per share peaked a few years back and have since softened a bit, likely reflecting higher financing costs, integration expenses from acquisitions, or other below‑the‑line items. Overall, the core business looks healthy and efficient, but the bottom line is not growing as fast as the top line, which is worth keeping in mind.

Balance Sheet

Balance Sheet The balance sheet shows a business that has become much more leveraged recently. Total assets have crept up, but debt has increased sharply, while reported equity has fallen to a relatively low level. That combination points to significant use of borrowing, probably to fund acquisitions or shareholder transactions. Cash on hand has improved from very thin levels but still looks modest relative to the size of the business and its debt. In simple terms, the company appears solid in scale but now carries a heavy debt load, which raises sensitivity to interest costs and refinancing conditions.

Cash Flow

Cash Flow Cash generation from operations has been consistently positive and fairly stable, which is a clear strength. After investment in new clinics, technology, and equipment, the business still produces solid free cash flow year after year. Capital spending is steady and manageable rather than aggressive, suggesting disciplined expansion rather than a high‑risk build‑out. The main tension is that while cash flows are dependable, the much higher debt means more of that cash may need to go to interest and debt repayment over time, leaving less flexibility if conditions weaken.

Competitive Edge

Competitive Edge Concentra holds a strong position in U.S. occupational health, supported by a very large clinic network and longstanding relationships with a wide range of employers, including many large corporations. Its focus on work‑related health, workers’ compensation, and direct employer contracts gives it a specialized niche that is harder for general healthcare providers to replicate. Recent acquisitions have further expanded its footprint and deepened its presence in onsite and near‑site clinics, reinforcing its appeal as a one‑stop partner for employers. The main competitive risks are ongoing integration of acquired businesses and the possibility of new technology‑driven entrants targeting narrow slices of its service offering.

Innovation and R&D

Innovation and R&D Innovation is centered on services and technology rather than traditional lab R&D. The company is pushing telemedicine tailored to workplace injuries, data‑driven case management, and analytics tools that help employers track and reduce injury costs. The appointment of a dedicated data and AI leader, exploration of wearables and predictive models, and the launch of a venture arm to back workforce‑health startups all point to a forward‑looking approach. Onsite clinics, mobile health units, and digital employer portals further differentiate the offering. The key uncertainty is execution: turning these initiatives into clear clinical and financial advantages at scale over time.

Summary

Concentra combines a stable, cash‑generative core business with an aggressive growth and technology strategy, especially in occupational health and onsite employer clinics. Operating performance looks solid, but headline earnings have not kept pace with revenue, and the balance sheet now carries much higher leverage. Competitive strengths include scale, specialized focus, and deep employer relationships, while innovation efforts in telehealth, data, and onsite services aim to deepen its moat. Future performance will hinge on successfully integrating acquisitions, managing the heavier debt burden, and converting its technology and analytics investments into sustained profitability gains.

NEWS

November 10, 2025 · 4:30 PM UTC

Concentra Appoints Jason Cooper as Chief Data, Analytics, and Artificial Intelligence Officer

Read more

November 6, 2025 · 4:36 PM UTC

CON EDISON REPORTS 2025 THIRD QUARTER EARNINGS

Read more

November 6, 2025 · 4:30 PM UTC

Concentra Group Holdings Parent, Inc. Announces Results For Its Third Quarter Ended September 30, 2025, Cash Dividend, and Raised FY 2025 Guidance

Read more

October 16, 2025 · 4:36 PM UTC

CON EDISON DECLARES COMMON STOCK DIVIDEND

Read more

October 6, 2025 · 4:30 PM UTC

Concentra® to Announce Third Quarter 2025 Results on Thursday, November 6, 2025

Read more